Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial of Prasinezumab in Early-Stage Parkinson’s Disease
Gennaro Pagano, Kirsten I. Taylor, Judith Anzures‐Cabrera, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 5, pp. 421-432
Open Access | Times Cited: 261

Showing 1-25 of 261 citing articles:

The pathogenesis of Parkinson's disease
Huw R. Morris, Maria Grazia Spillantini, Carolyn M. Sue, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 293-304
Open Access | Times Cited: 274
Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
Paolo Calabresi, Alessandro Mechelli, Giuseppina Natale, et al.
Cell Death and Disease (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 272
Trial of Cinpanemab in Early Parkinson’s Disease
Anthony E. Lang, Andrew Siderowf, Eric A. Macklin, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 5, pp. 408-420
Open Access | Times Cited: 233
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen Xu, Yong Chen, Yang Xu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 199
Lipopolysaccharide-Induced Model of Neuroinflammation: Mechanisms of Action, Research Application and Future Directions for Its Use
Anna Skrzypczak-Wiercioch, Kinga Sałat
Molecules (2022) Vol. 27, Iss. 17, pp. 5481-5481
Open Access | Times Cited: 146
Trial of Lixisenatide in Early Parkinson’s Disease
Wassilios G. Meissner, Philippe Rémy, Caroline Giordana, et al.
New England Journal of Medicine (2024) Vol. 390, Iss. 13, pp. 1176-1185
Closed Access | Times Cited: 122
α-Synuclein in synaptic function and dysfunction
Manu Sharma, Jacqueline Burré
Trends in Neurosciences (2022) Vol. 46, Iss. 2, pp. 153-166
Open Access | Times Cited: 95
Medical, surgical, and physical treatments for Parkinson's disease
Thomas Foltynie, Verónica Bruno, Susan H. Fox, et al.
The Lancet (2024) Vol. 403, Iss. 10423, pp. 305-324
Open Access | Times Cited: 73
Progression of clinical markers in prodromal Parkinson’s disease and dementia with Lewy bodies: a multicentre study
Stephen Joza, Joshua Shulman, Ki‐Young Jung, et al.
Brain (2023) Vol. 146, Iss. 8, pp. 3258-3272
Closed Access | Times Cited: 63
Neuropathology of incidental Lewy body & prodromal Parkinson’s disease
Thomas Koeglsperger, S Rumpf, Patricia Schließer, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 60
Advances in understanding the function of alpha-synuclein: implications for Parkinson’s disease
Paolo Calabresi, Giulia Di Lazzaro, Gioia Marino, et al.
Brain (2023) Vol. 146, Iss. 9, pp. 3587-3597
Open Access | Times Cited: 58
Alpha Synuclein: Neurodegeneration and Inflammation
Gianluigi Forloni
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5914-5914
Open Access | Times Cited: 55
The neuroprotective effects of targeting key factors of neuronal cell death in neurodegenerative diseases: The role of ER stress, oxidative stress, and neuroinflammation
Mohammad Sobhan Karvandi, Farzam Sheikhzadeh Hesari, Amir Reza Aref, et al.
Frontiers in Cellular Neuroscience (2023) Vol. 17
Open Access | Times Cited: 46
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease
Gennaro Pagano, Kirsten I. Taylor, Judith Anzures Cabrera, et al.
Nature Medicine (2024) Vol. 30, Iss. 4, pp. 1096-1103
Open Access | Times Cited: 39
Parkinson’s Disease
Caroline M. Tanner, Jill L. Ostrem
New England Journal of Medicine (2024) Vol. 391, Iss. 5, pp. 442-452
Closed Access | Times Cited: 31
Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
Christian Hölscher
Neuropharmacology (2024) Vol. 253, pp. 109952-109952
Open Access | Times Cited: 21
Loss of monomeric alpha-synuclein (synucleinopenia) and the origin of Parkinson's disease
Alberto J. Espay, Andrew Lees
Parkinsonism & Related Disorders (2024) Vol. 122, pp. 106077-106077
Open Access | Times Cited: 17
Synucleins: New Data on Misfolding, Aggregation and Role in Diseases
Andrei Surguchov, Alexei Surguchev
Biomedicines (2022) Vol. 10, Iss. 12, pp. 3241-3241
Open Access | Times Cited: 46
Current Treatments and New, Tentative Therapies for Parkinson’s Disease
Teresa Pardo-Moreno, Victoria García‐Morales, Nora Suleiman‐Martos, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 770-770
Open Access | Times Cited: 38
An Apple a Day to Keep the Parkinson's Disease Doctor Away?
Bastiaan R. Bloem, Erik Post, Deborah A. Hall
Annals of Neurology (2023) Vol. 93, Iss. 4, pp. 681-685
Open Access | Times Cited: 31
Translational molecular imaging and drug development in Parkinson’s disease
Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawoud, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 29
Multiple system atrophy: at the crossroads of cellular, molecular and genetic mechanisms
Nadia Stefanova, Gregor K. Wenning
Nature reviews. Neuroscience (2023) Vol. 24, Iss. 6, pp. 334-346
Closed Access | Times Cited: 29
Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease
Amica Corda Müller-Nedebock, Marieke C. J. Dekker, Matthew J. Farrer, et al.
npj Parkinson s Disease (2023) Vol. 9, Iss. 1
Open Access | Times Cited: 29
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert C. Pritchard, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6438-6438
Open Access | Times Cited: 29
Small-molecule LRRK2 inhibitors for PD therapy: Current achievements and future perspectives
Jiarui Hu, Dan Zhang, Keyue Tian, et al.
European Journal of Medicinal Chemistry (2023) Vol. 256, pp. 115475-115475
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top